Government authorities have given the A2 Milk Company (A2M) and its manufacturing partner, Synlait Milk (SM1), the green light to keep turning out A2M infant formula until at least the beginning of next year.
Manufacturer Synlait announced that its A2M China-label infant milk formula (IMF) had received State Administration for Market Renewal (SAMR).
This extension will allow Synlait to continue manufacturing A2 Milk until February 21, 2023, when the formula will need to be re-registered in China in accordance with the country's new GB food safety standards.
According to A2M, the two companies are now working "closely together" to get A2M's products registered under the new rules.
David Bortolussi, A2M CEO, stated:
"We are pleased that our current product registration has been renewed, effectively to late February 2023, and we will continue to work collaboratively with Synlait and SAMR related to the registration of our China-label IMF product formulated in line with China's new GB standards...
As a company, we are committed to the Chinese market and eager for the chance to provide parents and infants there with our newly formulated infant milk product."
The company also mentioned that New Zealand was in a good position with respect to China's registration processes because the Ministry for Primary Industries (MPI) had cooperation arrangements in place with Chinese regulators.
Roughly 20% of Synlait is owned by A2 Milk.
By 10:31 AM AEST, A2 Milk's stock price had risen 4.23 percent to $5.80, while Synlait's was flat at $3.12.